The Asia Pacific organoids market is expected to reach US$ 513.74 million in 2027 from US$ 97.02 million in 2019. The market is estimated to grow at a CAGR of 23.1% from 2020 to 2027.
Rising adoption of biobanking and tumor modelling and alternatives for animal testing models acting as kingpins are expected to augment the growth of the market. However, lack of expertise is likely to have a negative impact on the growth of the market in the coming years.
Organoids are tiny, self-organized three-dimensional tissue cultures that are derived from stem cells. Such cultures can be crafted to replicate much of the complexity of an organ, or to express selected aspects of it like producing only certain types of cells. Organoids grow from stem cells—cells that can divide indefinitely and produce different types of cells as part of their progeny. Organoids can range in size from less than the width of a hair to five millimeters.
Organoids are microscopic and self-organizing 3D structures, which are grown from stem cells in vitro. They review various structural and functional characteristics of their in vivo counterpart organs. This multipurpose technology has led to the development of several novel human cancer models. It is now possible to create indefinitely expanding organoids starting from the tumor tissue of individuals suffering from a range of carcinomas. Alternatively, CRISPR-based gene modification allows the engineering of organoid models of cancer by introducing any combination of cancer gene alterations to normal organoids. Tumor organoids, when combined with immune cells and fibroblasts, becomes a model for the cancer microenvironment enabling immune-oncology applications. Also, recent studies have proved that organoids have a place in personalized medicine approaches. Further, research and development activities have specified that tumoroid culturing is highly effectual in allowing the collection of various cancer subtypes from a large pool of patients. As organoids can be easily derived and expanded from single cancer cells, the adoption of organoids to mimic intra-tumor diversification in culture is increasing, which, in turn, is projected to propel the APAC organoids market during the forecast period.
China, Japan, India, Australia, and South Korea are the most affected countries due to increasing number of COVID-19 cases and associated deaths. Manufacturers and suppliers of medical devices are shifting their focus from regular organoids to the development and supply of COVID-19 essentials and medical devices used for respiratory issues. This scenario is expected to show an impact on the growth of organoids market in the Asia-Pacific aregion.
In 2019, the intestine segment accounted for the largest market share. The intestine segment holds a significant market share in the organoids market due to rise in prevalence of inflammatory bowel diseases (IBD) across the globe. IBD affects 300 per 100,000 people across the world. Further, rising adoption of new technologies among researchers and academia coupled with growing industry-academia collaborations for research, and technological advancements in 3D bioprinting would further offer lucrative opportunities in the review period.
A few secondary sources referred to while preparing the report of Asia Pacific organoids market are the World Health Organization, Korea Biomedicine Industry Association, Organization for Economic Co-operation and Development, and International Trade Administration.